# Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases

> **NCT07644754** · NA · NOT_YET_RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 27 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Metastatic Disease
- Prostate Cancer Metastatic to Bone

## Interventions

- **RADIATION:** Radiotherapy to the prostate and to PSMA-PET positive metastases

## Key facts

- **NCT ID:** NCT07644754
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2031-02
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644754, "Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*